67 results
Page 3 of 4
8-K
EX-1.2
3bvqw e7h
7 Oct 19
Ovid Therapeutics Announces Pricing of $32.5 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock
9:29pm
8-K
EX-1.1
d6u7p1r
7 Oct 19
Ovid Therapeutics Announces Pricing of $32.5 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock
9:29pm
424B5
l65y3 dlrkje5ca1473l
3 Oct 19
Prospectus supplement for primary offering
4:11pm
424B5
0440b1iqef akpszmi
3 Oct 19
Prospectus supplement for primary offering
4:07pm
424B5
1gr1lp9ypb5v0k90c
21 Feb 19
Prospectus supplement for primary offering
9:24pm
424B5
763g35bfjmn
21 Feb 19
Prospectus supplement for primary offering
9:22pm
8-K
EX-1.1
quk649uq eboaot20y
21 Feb 19
Ovid Therapeutics Announces Pricing of $30 Million of Securities in Concurrent Public Offerings of Common and Preferred Stock
4:53pm
8-K
EX-1.2
kk51p60o
21 Feb 19
Ovid Therapeutics Announces Pricing of $30 Million of Securities in Concurrent Public Offerings of Common and Preferred Stock
4:53pm
424B5
24lrr05
19 Feb 19
Prospectus supplement for primary offering
4:06pm
424B5
bjucne
19 Feb 19
Prospectus supplement for primary offering
4:04pm
8-K
EX-99.1
89kqx6jq5m83 n1edi
19 Feb 19
Results of Operations and Financial Condition
4:01pm
8-K
EX-99.1
dimd3q jmkn261n61le
7 Jan 19
Regulation FD Disclosure
6:31am
8-K
EX-99.1
f7tjqv8
6 Dec 18
Ovid Therapeutics Announces Plans to Move into a Phase 3 Trial in Pediatric Patients Based on End-of-Phase 2 Meeting for OV101 in Angelman Syndrome
8:05am
S-3
zvzrjx1zmp
1 Jun 18
Shelf registration
5:14pm